- news, features, articles and disease information for the swine industry


Artes Biotechnology Announces Collaboration with Boehringer Ingelheim

16 March 2015
Boehringer Ingelheim

GERMANY - ARTES Biotechnology has announced a collaboration with global pharmaceutical company, Boehringer Ingelheim Animal Health.

ARTES Biotechnology specialises in recombinant protein production, process and vaccine development from microbial expression systems.

ARTES’ expression system Hansenula polymorpha is the preferred technology for affordable mass vaccination and recommended by the World Health Organization (WHO) for these purposes. In combination with ARTES’ METAVAX® platform, this offers a new, unique and economical approach to low-cost mass production of safe and effective vaccines required in the veterinary field.

Michael Piontek, managing director of ARTES, stated: “This collaboration is another milestone in expanding our vaccine development expertise. We are more than confident that our technology platform is perfectly suited for the development of safe and cost efficient vaccines that are highly relevant for the veterinary market.”

Rolf-Dieter Günther, Head of Global Business Development and Licensing Animal Health for Boehringer Ingelheim, commented: “Partnering is a central part of our strategy. We are excited about this collaboration and the opportunity to develop more innovative vaccines for the animal health market.”


ThePigSite News DeskRead more Boehringer Ingelheim News here

Share This

News By

Related News

More News

EU pig prices under pressure

News from European Union   21 November 2018

Our Sponsors


Seasonal Picks

Animal Welfare Science, Husbandry and Ethics: The Evolving Story of Our Relationship with Farm Animals